San Juan, Puerto Rico – Puerto Rico is re-emerging as a key location for biopharmaceutical manufacturing and “reshoring” initiatives, according to the Biotechnology Innovation Organization (BIO). The assessment comes as the United States aims to strengthen its domestic biomanufacturing capabilities, and Puerto Rico is positioned to play a significant role in that effort.
John F. Crowley, CEO of BIO, recently concluded his first visit to the island on Thursday, March 13, 2026, to highlight its strategic importance for attracting investment within the U.S. Biomanufacturing sector. Crowley’s visit and subsequent statements signal a positive shift for Puerto Rico’s biomanufacturing industry, as reported by El Nuevo Día.
The renewed interest in Puerto Rico aligns with broader discussions surrounding the resilience of U.S. Supply chains and the require for geographically diverse manufacturing hubs. The island’s existing infrastructure and skilled workforce make it an attractive location for biomanufacturing companies looking to expand or relocate operations. This development could provide a boost to the Puerto Rican economy, which has faced challenges in recent years.
“Puerto Rico vuelve al juego de la biomanufactura,” Crowley stated, according to a post on the Facebook page of the Department of Economic Development and Commerce of Puerto Rico (DDECPR). This translates to “Puerto Rico returns to the game of biomanufacturing.”
While details of Crowley’s meetings and specific investment proposals haven’t been disclosed, BIO’s acknowledgement of Puerto Rico’s strategic value is a notable development. As Archyde.com reported, BIO has not yet released a detailed report outlining specific recommendations or investment targets for Puerto Rico, but further announcements are expected in the coming weeks. The timing of the visit underscores the growing focus on strengthening domestic manufacturing within the biotechnology sector.
El Nuevo Día also reported that Puerto Rico is consolidating its position as a strategic destination for biopharmaceutical manufacturing and reshoring, according to BIO.
